“Promising body-composition research, but the Akt explanation takes a detour.”
“Bimagrumab is being investigated as a drug that can reduce fat while increasing muscle or lean mass, by activating the Akt pathway.”
Clinical trials support the central takeaway that bimagrumab is under investigation and has produced substantial fat-mass loss alongside gains or preservation of lean mass in studied adults.
The mechanism is misstated: bimagrumab blocks activin type II receptors rather than simply working by activating Akt. Research also indicates its muscle-hypertrophy effects can occur through Akt-independent pathways.
The mechanism error does not materially overturn the post's main, cautiously framed claim about investigational body-composition effects.
Why Clear says this
A 2021 randomized phase 2 trial in 75 adults with type 2 diabetes and obesity found lower fat mass and higher lean mass with bimagrumab versus placebo. A larger 2026 phase 2 trial also found fat reduction and lean-mass preservation, including with semaglutide. These results are promising but remain phase 2 evidence, not proof of an approved or broadly established treatment.
Evidence
- In a 48-week phase 2 randomized trial, bimagrumab reduced fat mass by 20.5% and increased lean mass by 3.6% among adults with type 2 diabetes and overweight or obesity.
- A 2026 phase 2 trial in adults with obesity found bimagrumab-containing treatment reduced fat mass and preserved lean mass.
- Bimagrumab binds and inhibits activin type II receptors; experimental evidence does not support portraying Akt activation as its simple or required mechanism.
- FDA records identify bimagrumab as not approved for its prior orphan-designated indication; the post accurately calls it investigational.